STOCK TITAN

Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Alector, a clinical-stage biotechnology company, announced participation in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 2:00 p.m. PT. The live webcast will be accessible on Alector's Investors page, with a replay available for 90 days post-event. Alector is known for its innovative approach in immuno-neurology, targeting immune dysfunction to treat neurodegenerative diseases like Alzheimer’s and frontotemporal dementia.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022, at 2:00 p.m. PT.

A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for at least 90 days following the event.

About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Contacts:

1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com 

Argot Partners (investors)
Eric Kasper/Carrie McKim
Argot Partners
212.600.1902
alector@argotpartners.com


FAQ

What is Alector's participation in the Goldman Sachs Healthcare Conference 2022?

Alector will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 2:00 p.m. PT.

How can I watch the Alector fireside chat live?

The live webcast of the Alector fireside chat will be available on the Events & Presentations page within the Investors section of Alector's website.

How long will the Alector fireside chat replay be available?

A replay of the Alector fireside chat will be available on the website for at least 90 days following the event.

What is Alector known for in biotechnology?

Alector is known for pioneering immuno-neurology, focusing on treating neurodegenerative diseases by targeting immune dysfunction.

What diseases does Alector aim to treat?

Alector aims to treat neurodegenerative diseases, particularly Alzheimer's disease and frontotemporal dementia.

Alector, Inc.

NASDAQ:ALEC

ALEC Rankings

ALEC Latest News

ALEC Stock Data

169.42M
88.17M
9.97%
86.08%
4.11%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOUTH SAN FRANCISCO